Advancements and Challenges in the Treatment of AML
American Society of Clinical Oncology Educational Book · 2024-06 · 44 (3)
DOI: 10.1200/edbk_438662 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024-06. Verfasst von Yasmin Abaza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based induction chemotherapy (for all fit patients) or a single-agent hypomethylating agent (in unfit patients or those 75 years and older). While assessing patient fitness remains important, characterizing the disease biology has become critical to select the optimal initial therapy for each patient with more options available. FLT3 inhibitors, gemtuzumab ozogamicin, and CPX-351 have been shown to improve outcomes for specific subsets of patients. Venetoclax (VEN) with a hypomethylating agent (HMA) is the standard-of-care frontline regimen for most older patients, except perhaps for those with an IDH1 mutation where ivosidenib with azacitidine may also be considered. On the basis of the success seen with HMA/VEN in older patients, there is now increasing interest in incorporating VEN into frontline regimens in younger patients, with promising data from multiple early phase studies. This article focuses on recent updates and ongoing challenges in the management of AML, with a particular focus on the ongoing challenge of secondary AML and considerations regarding the selection of initial therapy in younger patients. An overview of common side effects and toxicities associated with targeted therapies is also presented here, along with recommended strategies to mitigate these risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
- Division of Hematology, University of Colorado School of Medicine, Aurora, CO.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Förderung
- NCI NIH HHS
Zitieren
APA
Abaza, Y., McMahon, C., & Garcia, J. S. (2024). Advancements and Challenges in the Treatment of AML. American Society of Clinical Oncology Educational Book, 44(3). https://doi.org/10.1200/edbk_438662
Vancouver
Abaza Y, McMahon C, Garcia JS. Advancements and Challenges in the Treatment of AML. American Society of Clinical Oncology Educational Book. 2024;44(3). doi:10.1200/edbk_438662
BibTeX
@article{Abaza2024,
author = {Abaza, Yasmin and McMahon, Christine and Garcia, Jacqueline S},
title = {Advancements and Challenges in the Treatment of AML},
journal = {American Society of Clinical Oncology Educational Book},
year = {2024},
volume = {44},
number = {3},
doi = {10.1200/edbk_438662}
}
EUVIMED